The All Ordinaries Index (ASX: XAO) is on a bit of a rollercoaster today.
At time of writing, the index is up 0.6% after almost dipping into the red in the early lunch hour.
This comes after investors, spooked by Russia's invasion of Ukraine, hit the sell button yesterday. That saw the All Ordinaries close for a 2.8% loss for the day.
While the index is clawing back some of its losses, these 2 All Ordinaries shares are heading sharply in the other direction.
2 ASX All Ordinaries shares hitting 52-week lows
First up we have Bravura Solutions Ltd (ASX: BVS). The ASX tech shares provides software solutions for the wealth management, life insurance, and funds administration industries.
The Bravura share price is down more than 17% today, sinking it to 52-week lows to $1.56.
This comes on the back of the release of its half year financial results today. While the reporting period saw some strong figures, management downgraded its net profit after tax (NPAT) guidance for the full 2022 financial year.
With the Bravura share price now down 47% in 12 months, is opportunity knocking on this beaten down All Ordinaries share?
According to Goldman Sachs it may well be. The broker has a buy rating on the stock, with its most recent price target (issued 24 November 2021) for Bravura of $3.70 per share. That's 137% above the current price.
Also hitting 52-week lows
Our second ASX All Ordinaries share hitting 52-week lows today is healthcare services provider, Integral Diagnostics Ltd (ASX: IDX).
The Integral Diagnostics share price is down 12% today to $3.45 per share. That brings its 12 months losses to 29%.
This comes after the company emerged from a 2-day trading halt today and following the release of its half year results yesterday, along with the announcement that it had agreed to acquire Peloton Radiology. While the results were solid, the company's dividend payout slipped.
Catch a falling knife? Or opportunity knocking?
According to Goldman Sachs, this All Ordinaries share also could be an opportunity.
Yesterday the broker had a buy rating on Integral Diagnostics, with a price target of $5. That's 45% above the current share price.
